- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05096338
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer (PCT)
Cardiotoxicity of Prostate Cancer Therapy: Mechanisms, Predictors, and Social Determinants of Health in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Bonnie Ky, MD, MSCE
- Phone Number: 215-573-6606
- Email: bonnie.ky@pennmedicine.upenn.edu
Study Contact Backup
- Name: Amanda Smith, MA
- Email: amanda.smith4@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Men older than 18 years of age Prostate cancer diagnosis planned for treatment with ≥6 months of ADT (with or without RT) for clinically localized, biochemically recurrent, or oligometastatic disease. Planned ADT regimens may include: GnRH agonists (goserelin, histrelin, leuprolide, triptorelin) with or without first-generation anti-androgens and GnRH antagonists (degarelix). Additional systemic agents, including second-generation androgen receptor signaling inhibitors, may be used in combination with GnRH agonist/antagonist therapies per provider clinical discretion.
Ability to provide informed consent
Exclusion Criteria:
Prior ADT injection within 6 months prior to enrollment Inability or unwillingness to provide consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Left Ventricular Ejection Fraction (LVEF)
Time Frame: through study completion (expected to be 15 years)
|
Absolute change in LVEF by echocardiogram at follow-up
|
through study completion (expected to be 15 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cancer therapy-related cardiac dysfunction (CTRCD)
Time Frame: through study completion (expected to be 15 years)
|
Incidence of CTRCD defined as at least a 10% absolute change in LVEF by echocardiogram at follow-up relative to baseline to a value < 50%
|
through study completion (expected to be 15 years)
|
Symptomatic Heart Failure (HF)
Time Frame: through study completion (expected to be 15 years)
|
Incidence of symptomatic heart failure (centrally adjudicated)
|
through study completion (expected to be 15 years)
|
Change in Longitudinal Strain
Time Frame: through study completion (expected to be 15 years)
|
Change in longitudinal strain by echo from baseline
|
through study completion (expected to be 15 years)
|
Change in Circumferential Strain
Time Frame: through study completion (expected to be 15 years)
|
Change in circumferential strain by echo from baseline
|
through study completion (expected to be 15 years)
|
Change in Diastolic function
Time Frame: through study completion (expected to be 15 years)
|
Change in diastolic function defined as E/e' by echo from baseline
|
through study completion (expected to be 15 years)
|
Change in Left Ventricular (LV) Mass
Time Frame: through study completion (expected to be 15 years)
|
Change in LV Mass by echo from baseline
|
through study completion (expected to be 15 years)
|
Change in Relative LV Wall Thickness
Time Frame: through study completion (expected to be 15 years)
|
Change in relative LV wall thickness from baseline
|
through study completion (expected to be 15 years)
|
Change in Ventricular-Arterial Coupling
Time Frame: through study completion (expected to be 15 years)
|
Change in Ventricular-Arterial Coupling defined as Ea/Ees by echo from baseline
|
through study completion (expected to be 15 years)
|
Change in LV Twist
Time Frame: through study completion (expected to be 15 years)
|
Change in LV Twist measured by 3D echo from baseline
|
through study completion (expected to be 15 years)
|
Change in LV Torsion
Time Frame: through study completion (expected to be 15 years)
|
Change in LV Torsion measured by 3D echo from baseline
|
through study completion (expected to be 15 years)
|
Change in NTproBNP
Time Frame: through study completion (expected to be 15 years)
|
Change in NTproBNP measured in batches from banked samples from baseline.
|
through study completion (expected to be 15 years)
|
Change in high-sensitivity troponin (hsTnT)
Time Frame: through study completion (expected to be 15 years)
|
Change in hs-TnT measured in batches from banked samples from baseline.
|
through study completion (expected to be 15 years)
|
Change in patient reported fatigue
Time Frame: through study completion (expected to be 15 years)
|
Change in Patient Reported Outcomes Information System (PROMIS) Fatigue Score from baseline.
A higher score corresponds to higher reported levels of fatigue.
|
through study completion (expected to be 15 years)
|
Change in patient reported quality of life
Time Frame: through study completion (expected to be 15 years)
|
Change in Patient Reported Outcomes Information System (PROMIS) Global Health score from baseline.
Higher scores indicate a healthier patient.
|
through study completion (expected to be 15 years)
|
Change in patient reported activity level
Time Frame: through study completion (expected to be 15 years)
|
Change in total weekly leisure activity in METS assessed by Godin Leisure Time Exercise Questionnaire from baseline.
|
through study completion (expected to be 15 years)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Bonnie Ky, MD, MSCE, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Heart Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Genital Neoplasms, Male
- Prostatic Diseases
- Radiation Injuries
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Cardiovascular Diseases
- Prostatic Neoplasms
- Drug-Related Side Effects and Adverse Reactions
- Cardiotoxicity
Other Study ID Numbers
- UPCC 12821
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Social Determinants of Health
-
University of Toledo Health Science CampusUnknownQuality of Life | Patient Satisfaction | Social Determinants of HealthUnited States
-
Indiana UniversityRecruitingMetastatic Cancer | Advanced CancerUnited States
-
Abramson Cancer Center at Penn MedicineAmerican Heart AssociationRecruitingCardiovascular Diseases | Breast Cancer | Drug-Related Side Effects and Adverse Reactions | CardiotoxicityUnited States
-
Abramson Cancer Center at Penn MedicineGilead SciencesRecruitingBreast Cancer | Social Determinants of Health (SDOH)United States
-
University of British ColumbiaCompletedCystic Fibrosis | Chronic Renal Insufficiency | Diabetes Mellitus Type ICanada
-
Hackensack Meridian HealthBecton, Dickinson and CompanyRecruiting
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Merck Sharp & Dohme LLCActive, not recruitingHIV InfectionUnited States, Russian Federation, Argentina, Australia, Canada, Chile, Colombia, Israel, Japan, New Zealand, Puerto Rico, South Africa, Switzerland, Taiwan, United Kingdom
-
Arcispedale Santa Maria Nuova-IRCCSCompleted
-
The University of Hong KongLok Sin Tong Benevolent Society, KowloonCompleted